Dapagliflozin Added to Usual Care in Individuals with Type 2 Diabetes Mellitus with Preexisting Cardiovascular Disease: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with a 2-Week Extension

Dapagliflozin Added to Usual Care in Individuals with Type 2 Diabetes Mellitus with Preexisting Cardiovascular Disease: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with a 2-Week Extension

To assess the efficacy of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, for the treatment of individuals with type 2 diabetes mellitus (T2DM) and preexisting cardiovascular disease (CVD). Randomized, double-blind, age-stratified (

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American Geriatrics Society (JAGS) 2014-07, Vol.62 (7), p.1252-1262
Hauptverfasser: Leiter, Lawrence A, Cefalu, William T, de Bruin, Tjerk W. A, Gause-Nilsson, Ingrid, Sugg, Jennifer, Parikh, Shamik J
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To assess the efficacy of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, for the treatment of individuals with type 2 diabetes mellitus (T2DM) and preexisting cardiovascular disease (CVD). Randomized, double-blind, age-stratified (
ISSN:0002-8614
DOI:10.1111/jgs.12881